Search results | influenza

Reports

Influenza Partnering

The Influenza Partnering provides understanding and access to the influenza partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Vertex seeking partner for its VX-787 influenza candidate

Vertex Pharmaceuticals showcased the latest results for influenza candidate VX-787 to attract partnering companies

Current Agreements Deal Analysis Update : November 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in October 2014.

Top 15 most partnered therapeutic trends in pharma industry

Current Partnering releases its first update of the article previously published last year on the most partnered therapeutic trends in pharma. The article analyses the most partnered therapeutic targets of 2009-2014 and identifies the areas that have gained in popularity since last year and the new areas that have entered the list

Industry trends in vaccine dealmaking – 2009 to 2014

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity.

Industry trends in infectious vaccines dealmaking – 2009 to 2014

Industry trends suggest that infectious vaccines research and development is an increasingly active component of healthcare business development. The last decade has witnessed a significant number of infectious vaccines partnering and M&A activity

CSL

CSL is a top pharmaceutical company based in Melbourne, Australia

Gilead Sciences partnering

Gilead Sciences is a top pharmaceutical company based in California, USA

Therapeutic partnering

Partnering with a therapeutic end point in mind.

Vertex Pharmaceuticals: Bringing smart people together to solve scientific problems

Vertex Pharmaceuticals is a global biotechnology company creating new possibilities in medicines, specifically for the diseases hepatitis C and Cystic Fibrosis.

Vertex: Partnering activity 2009-2014

Vertex Pharmaceuticals, a biotechnology company founded in 1989 and headquartered in Massachusetts has rapidly risen as one of the leading biotechnology companies in the world.

Events

Sorry, your search returned no results.


Deals

Vivaldi Biosciences biotech partners with Baxter for influenza vaccine assets

Vivaldi Biosciences has acquired from Baxter Healthcare research and development assets, including intellectual property, clinical data, know-how and materials, for LAIVs in which the gene for influenza nonstructural protein 1 has been fully deleted

CureVac in pharma licensing deal with Janssen for influenza vaccine

CureVac has entered into a collaboration and pharma licensing agreement with Janssen Pharmaceuticals

Scripps Research biopharma deals with Janssen on influenza research

The Scripps Research Institute announced a five-year biopharma deals agreement with Janssen Pharmaceuticals, a big pharma subsidiary, to collaborate on focused research projects in the infectious disease area, with the initial project targeting the influenza virus.

Vertex seeking partner for its VX-787 influenza candidate

Vertex Pharmaceuticals showcased the latest results for influenza candidate VX-787 to attract partnering companies

Johnson & Johnson and Crucell in strategic collaboration to develop innovative products, including therapies for influenza prevention and treatment

Under the flu-mAb collaboration, Crucell and Ortho-McNeil-Janssen Pharmaceuticals or its affiliates will share responsibilities to develop a universal flu-mAb product targeting all influenza A strains, including H1N1 strains (which cause seasonal flu and the current pandemic) and the H5N1 or avian strain (‘bird flu’).

Schering-Plough collaborates with World Health Organization to provide access to pandemic influenza vaccine technology to developing countries

Under the agreement, which was signed recently at WHO headquarters in Geneva, Nobilon has granted WHO a non-exclusive license to develop, register, manufacture, use and sell seasonal and pandemic live, attenuated, influenza vaccines (LAIV), produced on embryonated chicken eggs.

CSL has acquired the Flu vaccine business from Novartis

Novartis announced has entered an agreement that CSL has acquired its influenza vaccine business in a $275 million deal that will require regulatory approval before it closes by the end of the second half of 2015.

Visterra gets series B financing from Merck

Merck is investing $30 million in a Series B round of financing for Visterra.

Big pharma, Baxter sells its vaccines for $635 million

Big pharma, Baxter International has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer for a total cash consideration of $635 million, subject to certain adjustments.

Collaborative R&D agreement and licensing agreement for HSV vaccine and intellectual property

PaxVax has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections.